

# Usher Syndrome - Pipeline Review, H1 2020

<https://marketpublishers.com/r/U652678FAECEN.html>

Date: June 2020

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: U652678FAECEN

## Abstracts

Usher Syndrome - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome - Pipeline Review, H1 2020, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.

Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules,

respectively.

Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Usher Syndrome - Overview
- Usher Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Usher Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Usher Syndrome - Companies Involved in Therapeutics Development
- Amgen Inc
- Clearside BioMedical Inc
- Editas Medicine Inc
- Eloxx Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Odylia Therapeutics Inc
- ProQR Therapeutics NV
- Wave Life Sciences Ltd
- Usher Syndrome - Drug Profiles
- ASO-29 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BF-844 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EDIT-102 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ELX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate CLRN1 for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate CLRN1 for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate MYO7A for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate USH1C for Usher Syndrome 1C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate USH1G for Usher Type I Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate USH2A for Retinitis Pigmentosa and Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate USH2A for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Activate USH2A for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QR-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-421a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-461 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Usher Syndrome - Dormant Projects

Usher Syndrome - Discontinued Products

Usher Syndrome - Product Development Milestones

Featured News & Press Releases

May 02, 2019: Eloxx Pharmaceuticals presents positive new data at the Association for Research in Vision and Ophthalmology "ARVO" 2019 Annual Meeting

Jul 05, 2017: ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

May 01, 2017: ProQR to Present Data on QRX-411 at ARVO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Usher Syndrome, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Usher Syndrome - Pipeline by Amgen Inc, H1 2020  
Usher Syndrome - Pipeline by Clearside BioMedical Inc, H1 2020  
Usher Syndrome - Pipeline by Editas Medicine Inc, H1 2020  
Usher Syndrome - Pipeline by Eloxx Pharmaceuticals Inc, H1 2020  
Usher Syndrome - Pipeline by Ionis Pharmaceuticals Inc, H1 2020  
Usher Syndrome - Pipeline by Odylia Therapeutics Inc, H1 2020  
Usher Syndrome - Pipeline by ProQR Therapeutics NV, H1 2020  
Usher Syndrome - Pipeline by Wave Life Sciences Ltd, H1 2020  
Usher Syndrome - Dormant Projects, H1 2020  
Usher Syndrome - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Usher Syndrome, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Amgen Inc  
Clearside BioMedical Inc  
Editas Medicine Inc  
Eloxx Pharmaceuticals Inc  
Ionis Pharmaceuticals Inc  
Odylia Therapeutics Inc  
ProQR Therapeutics NV  
Wave Life Sciences Ltd



## I would like to order

Product name: Usher Syndrome - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/U652678FAECEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U652678FAECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970